Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease
Long-term sustained durability of the hypothetical drug, patient distribution based on baseline fibrosis stage, as well as initial treatment response rate are key factors that influence the cost-effectiveness of new MASLD drugs.
Authors
- Dae Won Jun (ORCID: https://orcid.org/0000-0002-2875-6139)
- Eileen Laureal Yoon (ORCID: https://orcid.org/0000-0003-0474-048X)
- Huiyul Park (ORCID: https://orcid.org/0000-0001-5044-8688)
- Hye‐Lin Kim (ORCID: https://orcid.org/0000-0001-9091-8787)
- Mimi Kim (ORCID: https://orcid.org/0000-0002-8266-0226)
- James S Park (ORCID: https://orcid.org/0000-0001-6248-4117)
- Jeong-Yeon Cho
Institutions
- University of Utah (US)
- Sahmyook University (KR)
- Hanyang University Seoul Hospital (KR)
- Myongji Hospital (KR)
- Hanyang University (KR)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3350/cmh.2025.0796
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hanyang University
- Korea Institute of Science and Technology